根据名称进行药物检索

Limbitrol 与 Luvox CR

Limbitrol 与 Luvox CR互相作用以及同时服用的可能性。

检测结果:

Limbitrol <> Luvox CR

现实性: 07.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

问问你的医生在使用之前阿米替林与沙明这样可以提高你的血液水平的阿米替林. 这种组合可能造成的副作用，例如昏昏欲睡、口干、视力模糊便秘、排尿或比平常少。跟你的医生之前使用这些药物在一起。你可能需要的剂量调整或特别的测试，以安全地把这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予与沙明可显着增加的等离子体浓度的一些三环抗抑郁药(机师). 拟议的机制是沙明的抑制作用的多个肝脏微粒体酶参与的新陈代谢的清关机师. 轻度至中度增加，在血浆水平已经报告了对地昔帕明，同时显着增加了几倍，已报告，对氯、丙咪嗪和曲米帕明. Pharmacodynamically，该组合的沙明(或任何其他选择性的血清素再吸收抑制剂)和TCA可能会加强风险的血清素综合症，这是一个罕见的，但是严重的和潜在的致命状况的思想导致过度刺激的脑干5HT1A受体。

管理：在一般情况下，使用沙明(或其他Ssri)与机师应该可以避免的，如果可能的话，或其谨慎处理，如果潜在的利益被认为大于风险。药物反应和等离子体TCA级别应监测更密切地每当沙明是加入或撤离治疗的患者中稳定在他们现有的抗抑郁治疗方案，并TCA剂量调整是必要的。患者应密切监测为的迹象和症状的TCA毒性(例如，镇静、口干、视力模糊便秘、尿潴留)和/或过量的血清素的活动(例如，中枢神经系统烦躁不安，改变意识、混乱、肌阵挛、共济失调、腹部痉挛、次高烧、颤抖、瞳孔扩张、发汗解表、高血压、心动过速).

来源

Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5
Ereshefsky L, Riesemman C, Lam YW "Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6." Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9
Popli AP, Baldessarini RJ, Cole JO "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 51 (1994): 666-7
Skjelbo E, Brosen K "Inhibitors of imipramine metabolism by human liver microsomes." Br J Clin Pharmacol 34 (1992): 256-61
Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P "Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients." Pharmacol Res 31 (1995): 347-53
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP "Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects." Ther Drug Monit 15 (1993): 243-6
Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99
Taylor D "Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses." Br J Psychiatry 167 (1995): 575-80
Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP "Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients." Int J Clin Pharmacol Res 13 (1993): 167-71
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4
Spina E, Campo GM, Avenoso A, et al "Interaction between fluvoxamine and imipramine/desipramine in four patients." Ther Drug Monit 14 (1992): 194-6
Maskall DD, Lam RW "Increased plasma concentration of imipramine following augmentation with fluvoxamine." Am J Psychiatry 150 (1993): 1566
"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI "Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants." J Clin Psychopharmacol 15 (1995): 125-31
Seifritz E, Holsboertrachsler E, Hemmeter U, Eap CB, Baumann P "Increased trimipramine plasma levels during fluvoxamine comedication." Eur Neuropsychopharmacol 4 (1994): 15-20
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Bertschy G, Vandel S, Vandel B, Allers G, Volmat R "Fluvoxamine-tricyclic antidepressant interaction. An accidental finding." Eur J Clin Pharmacol 40 (1991): 119-20